World health is generally improving, with fewer people dying from infectious diseases, and
therefore chronic diseases are more prevalent. 1 In that context, the burden of chronic …

1. Badagliacca R, DLAlto M, Ghio S, Argiento P, Bellomo V, Brunetti ND, et al. Risk reduction
and hemodynamics with initial combination therapy in pulmonary arterial hypertension. Am J …

1. Chung L, Liu J, Parsons L, et al. Characterization of connective tissue disease-associated
pulmonary arterial hypertension from REVEAL: identifying systemic sclerosis as a unique …

The field of pulmonary vascular disease remains a rapidly growing area of research. In
2014, investigators discovered new genetic determinants of pulmonary hypertension (PH) …

The Pulmonary Hypertension Association Registry (PHAR) became aware of an error in
coding of one of the quality of life metrics, the SF‐12. The coding error affected both the …

Background REVEAL (The Registry to Evaluate Early and Long-term Pulmonary Arterial
Hypertension Disease Management) provides current demographics of patients with group …

Rationale: Ongoing clinical trials of emerging therapies targeting unaddressed drivers of
pathogenesis are key to providing access to novel therapies and potentially improving …

FINANCIAL/NONFINANCIAL DISCLOSURES: The authors have reported to CHEST the
following: BJP has received speaker and consultancy fees from Novartis, Gilead, Pfizer …

(AJRCCM), also known as the Blue Journal. The first issue was published in March 1917
under the title of the American Review of Tuberculosis after considerable discussion and …

Pulmonary arterial hypertension (PAH) has had a significant increase in attention over the
last 18 years. This has been driven simultaneously by the advent of new treatments for this …